Skip to main content

Emergent Logo

GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).

 

{iframe}https://www.globenewswire.com/news-release/2021/04/05/2204096/0/en/Emergent-BioSolutions-On-Track-with-Respect-to-COVID-19-Contractual-Commitments-Receives-Modified-Task-Order-from-the-U-S-Department-of-Health-Human-Services-to-Support-the-Opportu.html{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.